European Commission green lights Servier's Tibsovo
Treatment concerns patients with IDH1-mutated acute myeloid leukaemia and IDH1-mutated cholangiocarcinoma - News - PharmaTimes
Source: pharmatimes.com
📰 Philippe Gonnard News
Philippe Gonnard News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Philippe Gonnard. Real-time updates on events, politics, business and more.
Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
/PRNewswire/ -- Servier, a global pharmaceutical group, today announced that the European Commission (EC) has approved Tibsovo® (ivosidenib tablets) as a...
Source: prnewswire.com
Servier submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO (ivosidenib tablets) for patients with IDH1-mutated Acute Myeloid Leukemia (AML) and Cholangiocarcinoma
- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme - TIBSOVO is the first IDH1 mutation specific targeted therapy submitted in Europe - The submission
France General Prnewswire Servier Kostenloser Wertpapierhandel Claude Bertrand Philippe Gonnard European Union
Source: finanznachrichten.de
Servier submits a Marketing Authorization Application to the European Medicines Agency (EMA) for TIBSOVO® (ivosidenib ta
-- TIBSOVO is an inhibitor of the mutated isocitrate dehydrogenase-1(IDH1) enzyme -- TIBSOVO is the first...
France General Prnewswire Servier Claude Bertrand Philippe Gonnard European Union European Medicines Agency
Source: europapress.es